Skip to main content
Erschienen in: Heart and Vessels 7/2018

29.12.2017 | Original Article

The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure

verfasst von: Tetsuya Takahashi, Tetsu Watanabe, Tetsuro Shishido, Ken Watanabe, Takayuki Sugai, Taku Toshima, Daisuke Kinoshita, Miyuki Yokoyama, Harutoshi Tamura, Satoshi Nishiyama, Takanori Arimoto, Hiroki Takahashi, Tamon Yamanaka, Takuya Miyamoto, Isao Kubota

Erschienen in: Heart and Vessels | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Liver abnormalities have a strong impact on clinical outcomes in patients with heart failure (HF), and are known as cardio-hepatic syndrome. The non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) has been developed to identify liver fibrosis in patients with NAFLD. It remains to be determined whether NFS is associated with cardiovascular prognosis in patients with chronic heart failure (CHF). We calculated NFS in 516 patients with CHF admitted to our hospital. The clinical endpoints were deaths due to progressive HF, myocardial infarction, stroke, and sudden cardiac death, and rehospitalization for worsening HF. There were 173 cardiovascular events noted during a median follow-up of 464 days. Patients with cardiovascular events showed a higher NFS as compared with those without. We divided the patients into four groups according to quartiles of NFS. The proportion of New York Heart Association functional class III/IV and serum brain natriuretic peptide levels were increased with increasing NFS. Kaplan–Meier analysis revealed that cardiovascular event rate was increased with increasing NFS in patients with CHF. In multivariate Cox proportional hazards analysis, NFS was independently associated with cardiovascular events after adjustment for confounding factors. Elevated NFS was associated with unfavorable outcomes in patients with CHF. Liver fibrosis assessed by NFS may provide valuable prognostic information in patients with CHF.
Literatur
2.
Zurück zum Zitat Rauchhaus M, Coats AJ, Anker SD (2000) The endotoxin-lipoprotein hypothesis. Lancet 356:930–933CrossRefPubMed Rauchhaus M, Coats AJ, Anker SD (2000) The endotoxin-lipoprotein hypothesis. Lancet 356:930–933CrossRefPubMed
3.
Zurück zum Zitat Sundaram V, Fang JC (2016) Gastrointestinal and liver issues in heart failure. Circulation 133:1696–1703CrossRefPubMed Sundaram V, Fang JC (2016) Gastrointestinal and liver issues in heart failure. Circulation 133:1696–1703CrossRefPubMed
4.
Zurück zum Zitat van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA (2010) Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 16:84–90CrossRefPubMed van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA (2010) Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 16:84–90CrossRefPubMed
5.
Zurück zum Zitat Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D (2000) Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 140:111–120CrossRefPubMed Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D (2000) Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 140:111–120CrossRefPubMed
6.
Zurück zum Zitat Kubo SH, Walter BA, John DH, Clark M, Cody RJ (1987) Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics. Arch Intern Med 147:1227–1230CrossRefPubMed Kubo SH, Walter BA, John DH, Clark M, Cody RJ (1987) Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics. Arch Intern Med 147:1227–1230CrossRefPubMed
7.
Zurück zum Zitat Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB (2009) Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 11:170–177CrossRefPubMedPubMedCentral Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB (2009) Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 11:170–177CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Myers RP, Cerini R, Sayegh R, Moreau R, Degott C, Lebrec D, Lee SS (2003) Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 37:393–400CrossRefPubMed Myers RP, Cerini R, Sayegh R, Moreau R, Degott C, Lebrec D, Lee SS (2003) Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 37:393–400CrossRefPubMed
9.
Zurück zum Zitat Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854CrossRefPubMed Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854CrossRefPubMed
10.
Zurück zum Zitat Kotronen A, Yki-Jarvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38CrossRefPubMed Kotronen A, Yki-Jarvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38CrossRefPubMed
11.
Zurück zum Zitat Targher G, Marra F, Marchesini G (2008) Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51:1947–1953CrossRefPubMed Targher G, Marra F, Marchesini G (2008) Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51:1947–1953CrossRefPubMed
13.
Zurück zum Zitat Treeprasertsuk S, Bjornsson E, Enders F, Suwanwalaikorn S, Lindor KD (2013) NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 19:1219–1229CrossRefPubMedPubMedCentral Treeprasertsuk S, Bjornsson E, Enders F, Suwanwalaikorn S, Lindor KD (2013) NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 19:1219–1229CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kim D, Kim WR, Kim HJ, Therneau TM (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57:1357–1365CrossRefPubMedPubMedCentral Kim D, Kim WR, Kim HJ, Therneau TM (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57:1357–1365CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Takahashi Y, Kurosaki M, Tamaki N, Yasui Y, Hosokawa T, Tsuchiya K, Nakanishi H, Itakura J, Izumi N (2015) Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. Hepatol Res 45:667–675CrossRefPubMed Takahashi Y, Kurosaki M, Tamaki N, Yasui Y, Hosokawa T, Tsuchiya K, Nakanishi H, Itakura J, Izumi N (2015) Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. Hepatol Res 45:667–675CrossRefPubMed
16.
Zurück zum Zitat Valbusa F, Bonapace S, Agnoletti D, Scala L, Grillo C, Arduini P, Turcato E, Mantovani A, Zoppini G, Arcaro G, Byrne C, Targher G (2017) Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS One 12:e0173398CrossRefPubMedPubMedCentral Valbusa F, Bonapace S, Agnoletti D, Scala L, Grillo C, Arduini P, Turcato E, Mantovani A, Zoppini G, Arcaro G, Byrne C, Targher G (2017) Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS One 12:e0173398CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Kutsuzawa D, Arimoto T, Watanabe T, Shishido T, Miyamoto T, Miyashita T, Takahashi H, Niizeki T, Takeishi Y, Kubota I (2012) Ongoing myocardial damage in patients with heart failure and preserved ejection fraction. J Cardiol 60:454–461CrossRefPubMed Kutsuzawa D, Arimoto T, Watanabe T, Shishido T, Miyamoto T, Miyashita T, Takahashi H, Niizeki T, Takeishi Y, Kubota I (2012) Ongoing myocardial damage in patients with heart failure and preserved ejection fraction. J Cardiol 60:454–461CrossRefPubMed
18.
Zurück zum Zitat Eckardt KU, Berns JS, Rocco MV, Kasiske BL (2009) Definition and classification of CKD: the debate should be about patient prognosis—a position statement from KDOQI and KDIGO. Am J Kidney Dis 53:915–920CrossRefPubMed Eckardt KU, Berns JS, Rocco MV, Kasiske BL (2009) Definition and classification of CKD: the debate should be about patient prognosis—a position statement from KDOQI and KDIGO. Am J Kidney Dis 53:915–920CrossRefPubMed
19.
Zurück zum Zitat The METAVIR group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 20(1 Pt 1):15–20 The METAVIR group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 20(1 Pt 1):15–20
20.
Zurück zum Zitat Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J (2013) Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 145(782–789):e784 Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J (2013) Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 145(782–789):e784
21.
Zurück zum Zitat Moller S, Bernardi M (2013) Interactions of the heart and the liver. Eur Heart J 34:2804–2811CrossRefPubMed Moller S, Bernardi M (2013) Interactions of the heart and the liver. Eur Heart J 34:2804–2811CrossRefPubMed
22.
Zurück zum Zitat Birrer R, Takuda Y, Takara T (2007) Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 46:1063–1070CrossRefPubMed Birrer R, Takuda Y, Takara T (2007) Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 46:1063–1070CrossRefPubMed
23.
Zurück zum Zitat Seeto RK, Fenn B, Rockey DC (2000) Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 109:109–113CrossRefPubMed Seeto RK, Fenn B, Rockey DC (2000) Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 109:109–113CrossRefPubMed
24.
Zurück zum Zitat Myers RP, Lee SS (2000) Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 6:S44–S52CrossRefPubMed Myers RP, Lee SS (2000) Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 6:S44–S52CrossRefPubMed
25.
Zurück zum Zitat Valentova M, von Haehling S, Doehner W, Murin J, Anker SD, Sandek A (2013) Liver dysfunction and its nutritional implications in heart failure. Nutrition 29:370–378CrossRefPubMed Valentova M, von Haehling S, Doehner W, Murin J, Anker SD, Sandek A (2013) Liver dysfunction and its nutritional implications in heart failure. Nutrition 29:370–378CrossRefPubMed
27.
Zurück zum Zitat Mathison JC, Ulevitch RJ (1979) The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 123:2133–2143PubMed Mathison JC, Ulevitch RJ (1979) The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 123:2133–2143PubMed
28.
Zurück zum Zitat Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353:1838–1842CrossRefPubMed Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353:1838–1842CrossRefPubMed
29.
Zurück zum Zitat Yokoyama M, Watanabe T, Otaki Y, Takahashi H, Arimoto T, Shishido T, Miyamoto T, Konta T, Shibata Y, Daimon M, Ueno Y, Kato T, Kayama T, Kubota I (2016) Association of the aspartate aminotransferase to alanine aminotransferase ratio with BNP level and cardiovascular mortality in the general population: The Yamagata Study 10-year follow-up. Dis Markers 2016:4857917CrossRefPubMedPubMedCentral Yokoyama M, Watanabe T, Otaki Y, Takahashi H, Arimoto T, Shishido T, Miyamoto T, Konta T, Shibata Y, Daimon M, Ueno Y, Kato T, Kayama T, Kubota I (2016) Association of the aspartate aminotransferase to alanine aminotransferase ratio with BNP level and cardiovascular mortality in the general population: The Yamagata Study 10-year follow-up. Dis Markers 2016:4857917CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Samsky MD, Patel CB, DeWald TA, Smith AD, Felker GM, Rogers JG, Hernandez AF (2013) Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol 61:2397–2405CrossRefPubMed Samsky MD, Patel CB, DeWald TA, Smith AD, Felker GM, Rogers JG, Hernandez AF (2013) Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol 61:2397–2405CrossRefPubMed
32.
Zurück zum Zitat Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC (2008) Albumin levels predict survival in patients with systolic heart failure. Am Heart J 155:883–889CrossRefPubMed Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC (2008) Albumin levels predict survival in patients with systolic heart failure. Am Heart J 155:883–889CrossRefPubMed
33.
Zurück zum Zitat Lopez Castro J, Almazan Ortega R, De Juan Perez, Romero M, Gonzalez Juanatey JR (2010) Mortality prognosis factors in heart failure in a cohort of North-West Spain. EPICOUR study. Rev Clin Esp 210:438–447CrossRefPubMed Lopez Castro J, Almazan Ortega R, De Juan Perez, Romero M, Gonzalez Juanatey JR (2010) Mortality prognosis factors in heart failure in a cohort of North-West Spain. EPICOUR study. Rev Clin Esp 210:438–447CrossRefPubMed
34.
Zurück zum Zitat Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59:998–1005CrossRefPubMedPubMedCentral Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59:998–1005CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233CrossRefPubMed Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233CrossRefPubMed
Metadaten
Titel
The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure
verfasst von
Tetsuya Takahashi
Tetsu Watanabe
Tetsuro Shishido
Ken Watanabe
Takayuki Sugai
Taku Toshima
Daisuke Kinoshita
Miyuki Yokoyama
Harutoshi Tamura
Satoshi Nishiyama
Takanori Arimoto
Hiroki Takahashi
Tamon Yamanaka
Takuya Miyamoto
Isao Kubota
Publikationsdatum
29.12.2017
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 7/2018
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-017-1113-1

Weitere Artikel der Ausgabe 7/2018

Heart and Vessels 7/2018 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.